Copernicus Capital Management as of Dec. 31, 2020
Portfolio Holdings for Copernicus Capital Management
Copernicus Capital Management holds 15 positions in its portfolio as reported in the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical (BMRN) | 14.7 | $940k | 11k | 87.69 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 11.4 | $729k | 3.1k | 236.30 | |
| Bristol Myers Squibb (BMY) | 11.0 | $703k | 11k | 62.06 | |
| Abbvie (ABBV) | 7.8 | $501k | 4.7k | 107.14 | |
| Rocket Pharmaceuticals (RCKT) | 6.8 | $439k | 8.0k | 54.88 | |
| Teladoc (TDOC) | 6.1 | $389k | 1.9k | 200.10 | |
| Iqvia Holdings (IQV) | 5.8 | $375k | 2.1k | 179.08 | |
| Igm Biosciences (IGMS) | 5.5 | $353k | 4.0k | 88.25 | |
| Gw Pharmaceuticals Ads | 5.0 | $322k | 2.8k | 115.50 | |
| Tg Therapeutics (TGTX) | 4.7 | $304k | 5.8k | 51.99 | |
| Neurocrine Biosciences (NBIX) | 4.6 | $296k | 3.1k | 95.82 | |
| Fate Therapeutics (FATE) | 4.6 | $295k | 3.2k | 91.05 | |
| Arena Pharmaceuticals Com New | 4.5 | $287k | 3.7k | 76.74 | |
| Alnylam Pharmaceuticals (ALNY) | 4.1 | $260k | 2.0k | 130.00 | |
| Translate Bio | 3.5 | $223k | 12k | 18.44 |
